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ABSTRACT: Small oligomers of the protein α-synuclein
(αS) are highly cytotoxic species associated with
Parkinson’s disease (PD). In addition, αS can form co-
aggregates with its mutational variants and with other
proteins such as amyloid-β (Aβ) and tau, which are
implicated in Alzheimer’s disease. The processes of self-
oligomerization and co-oligomerization of αS are, however,
challenging to study quantitatively. Here, we have utilized
single-molecule techniques to measure the equilibrium
populations of oligomers formed in vitro by mixtures of wild-type αS with its mutational variants and with Aβ40, Aβ42,
and a fragment of tau. Using a statistical mechanical model, we find that co-oligomer formation is generally more
favorable than self-oligomer formation at equilibrium. Furthermore, self-oligomers more potently disrupt lipid
membranes than do co-oligomers. However, this difference is sometimes outweighed by the greater formation propensity
of co-oligomers when multiple proteins coexist. Our results suggest that co-oligomer formation may be important in PD
and related neurodegenerative diseases.
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neurodegeneration
The aggregation of the protein α-synuclein (αS) fromits soluble monomeric form into amyloid fibrils isassociated with a range of devastating neurodegener-
ative disorders such as Parkinson’s disease (PD) and a series of
related synucleinopathies.1 In these conditions, amyloid fibrils
of αS are segregated into cytoplasmic brain inclusions, Lewy
bodies, or Lewy neurites,2 although molecular complexes
consisting of a small number of αS monomers, termed
oligomers, are increasingly recognized as the most-cytotoxic
forms, giving rise to the disease etiology.3−7 It has also been
found that single-residue mutational variants of the protein,
including A30P, E46K, and A53T, are associated with familial
forms of PD.8−10 Moreover, aggregates of αS are observed in
more than half of the patients suffering from Alzheimer’s
disease (AD) along with the more-characteristic deposits of the
amyloid-β (Aβ) peptide and the protein tau.11 The co-
occurrence of the aggregates of αS, Aβ, and tau has been
reported in a variety of neurodegenerative conditions, and it
has been suggested that this enhancement could be due to co-
interactions between the proteins.12
αS has been shown in vitro to assemble into a large variety of
oligomers with distinct morphologies, structures, and func-
tional properties. Such oligomers can be formed via different
mechanisms and include non-fibrillar off-pathway species and
prefibrillar intermediates of the amyloid fibril formation
process.7,13−16 The mutational variants of αS have been
found to affect the rates of αS aggregation17−19 and oligomer
formation20 and to alter its interactions with lipid mem-
branes.21 The effects of the amino acid substitutions on the
rate of oligomer formation and the number of oligomers
remain unclear. Previous studies have reported either
increased4,18,22 or unaltered20 levels of oligomers formed by
the mutational variants relative to wild-type αS. Additionally,
the formation of co-oligomers between different variants of αS
has been observed to occur in aqueous solution.23
In addition to its ability to self-assemble into a variety of
oligomeric species, αS has been reported to interact with other
proteins, including Aβ and tau. For example, the effects of αS
and Aβ cointeraction on the aggregation of Aβ42 in vitro have
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recently been delineated,24 and the direct binding between αS
and Aβ40 and Aβ42 in solution has been characterized25−27 as
well as the direct interaction of αS and tau.28−30 The formation
of co-oligomers containing both αS and Aβ has been predicted
by several molecular dynamics simulations.31−33 Furthermore,
the formation of a dimer composed of αS and Aβ domains
upon their coordination to Cu2+ has been reported,34 and the
formation of co-oligomers of αS and tau has been observed in
vitro.35 The accumulation of co-oligomers of αS and tau in the
human brain has been shown using novel conformational-
specific antibodies.36 In addition, the formation of co-
oligomers of αS with Aβ and tau in human red blood cells
has recently been reported.37
Despite the accumulating evidence that αS can form self-
oligomers as well as co-oligomers with other proteins, the
extent of formation and the properties of these co-oligomeric
species remain to be determined and quantified. Most in vitro
investigations, particularly at low physiologically relevant
protein concentrations, have focused on the self-oligomeriza-
tion of αS because its co-oligomerization is difficult to detect
and quantify under these conditions. A comprehensive
characterization of the self-oligomerization process of αS and
its co-oligomerization with the mutational variants or Aβ and
with tau can help to compare their relative abundances, and
functional assays can reveal the relative cytotoxicities of the
self- and co-oligomeric species. To address these issues, we
have combined the highly sensitive single-molecule two-color
coincidence detection (sm-TCCD) technique,38 which enables
the selective detection of both self- or co-oligomeric species,
with statistical mechanical modeling.39 Using these method-
ologies, we have characterized the self-oligomerization of wild-
type αS; its co-oligomerization with the mutational variants
A30P, A53T, and E46K; and its co-oligomerization with Aβ40
and Aβ42 and tau construct k18, which contains four repeats
of the aggregation-prone region of full-length tau,40 at
physiologically relevant protein concentrations in aqueous
solution. We have derived the equilibrium free energies of
oligomer formation for the studied protein combinations,
enabling a quantitative comparison of the self- and co-
oligomerization processes. Furthermore, we have investigated
the ability of the characterized self- and co-oligomers to
permeabilize lipid vesicles, allowing us to quantify and compare
their potential for lipid membrane disruption.
RESULTS AND DISCUSSION
TCCD Measurements of the Formation of Self-
Oligomers. We first performed sm-TCCD measurements of
self-oligomer formation by wild-type αS (subsequently
abbreviated as “WT”), A30P, A53T, and E46K αS using singly
labeled monomers bearing Alexa Fluor 488 (AF488) and Alexa
Fluor 594 (AF594) fluorophores. These fluorescent labels were
incorporated at residue 90 of αS molecules, which has been
shown not to perturb its aggregation propensity in our
previous work.7 In the experiments, samples containing a 1:1
stoichiometric ratio of AF488 and AF594-labeled monomers of
the same protein were combined over a wide range of initial
total protein concentrations ranging from low-nanomolar
concentrations to 3 μM, corresponding to the reported range
of the physiological abundance of αS.41−43 Solutions were
incubated under quiescent conditions for 72 h at 37 °C in a
buffer of physiological pH and ionic strength (defined in the
Methods section) to generate equilibrium populations of
oligomers. Such quiescent conditions have been previously
shown to generate αS oligomers but not fibrils.15,44,45 Note,
however, that no oligomer enrichment steps are employed in
our preparation in contrast to previously reported protocols.15
Indeed, the absence of fibril formation under these incubation
conditions was confirmed by transmission electron microscopy
(TEM) (see the Supporting Information). Furthermore, it was
verified that incubation for 72 h is sufficient to generate
equilibrium populations of oligomers, even for the A30P
isoform, which is characterized by the slowest aggregation
kinetics20,21 (Figure S2). In addition to αS, we also analyzed
the self-oligomerization of the Alexa Fluor (AF)-labeled
Figure 1. Equilibrium populations of self-oligomers plotted against the total initial protein concentrations. A total of three to five separate
samples were analyzed for each initial concentration of monomeric protein. The resulting values are represented by red crosses, and the fit to
a single-peptide oligomerization model is shown as a solid line. The shaded bounds represent the fitting error derived using nonparametric
bootstrapping, as detailed in the Methods section.
ACS Nano Article
DOI: 10.1021/acsnano.8b03575
ACS Nano 2018, 12, 10855−10866
10856
construct of tau protein k18, which comprises the central
region of this protein that is included in the microtubule
binding region and is frequently used to study tau
aggregation.46,47 For the experiments with k18, the same
concentrations and incubation conditions were used as with αS
isoforms to enable a direct comparison of the oligomerization
potential of both proteins.
During the incubation of protein solutions containing 1:1
ratios of AF488- and AF594-labeled monomers of αS and of
the tau construct, the oligomers containing both fluorescent
dyes were formed and were quantified by sm-TCCD.38 For the
sm-TCCD measurement, the withdrawn protein solutions
were immediately diluted to pM concentrations to enable
single-molecule analysis, and continuously passed through a
microfluidic device mounted on a single-molecule fluorescence
microscope to reduce the detection time, as previously
detailed.48 We previously verified that oligomers remained
stable during single-molecule measurements under the same
conditions.49 The solutions were excited by overlapped and
focused 488 and 594 nm laser beams, and fluorescence bursts
from AF488 and AF594 were simultaneously detected in the
two separate emission channels. Thus, AF488-labeled mole-
cules gave rise to discrete noncoincident fluorescence bursts in
the AF488 channel, while AF594-labeled molecules lead to
fluorescence bursts in the AF594 channel. Any fluorescence
bursts that were coincident in both channels corresponded to
the oligomers bearing both AF488 and AF594. These dual-
labeled species were distinguished from the excess of singly
labeled species and quantified by the criterion of temporal
coincidence according to eq 1 (see the Methods section). Note
that this approach allows the selective monitoring and
quantification of only the dual-labeled oligomer species and
not singly labeled species, and we therefore refer to the
resulting oligomer concentrations as “apparent oligomer
concentrations”. In addition, the characterization of their
exact physical sizes or structures is beyond the scope of this
technique. We confirmed the absence of any direct interactions
between the free AF dyes used in our experiments by doing
control experiments using free AF488 and AF594 in aqueous
buffer, as described in the Supporting Information and Figure
S2. The resulting plots of the apparent concentrations of self-
oligomers of αS A30P, A53T, E46K, and WT and of tau k18
are shown in Figure 1a−e. The data show that the oligomer
populations formed under these conditions are below 200 nM,
highlighting the challenge of studying these species by less
sensitive bulk experimental techniques. The oligomer
populations of the αS variants A30P, A53T, and E46K reached
higher levels than the WT protein, with E46K giving the
highest apparent oligomer concentrations. The highest
apparent equilibrium concentrations of oligomers were
observed at the highest total starting αS concentrations, as
expected by mass action, in agreement with our previous study
of oligomer formation by αS.49 The apparent concentrations of
oligomers formed by k18 were mostly below 10 nM, which is
consistent with the expected low aggregation propensity of this
protein in aqueous buffer solution in the absence of
aggregation inducers.46,47 They were nevertheless sufficiently
above the background, confirming the formation of a low
population of oligomeric species under the incubation
conditions used here (Figure S2).
TCCD Measurements of the Formation of Co-
Oligomers. We next set out to determine whether or not
αS WT could co-oligomerize with its mutational variants, as
well as with Aβ40, Aβ42, and k18, by combining equimolar
ratios of the WT with the other proteins. The 1:1 mixtures of
αS WT with its mutational variants are likely to be
physiologically relevant as the variants of αS are known to
coexist with αS WT in vivo.8−10 The interactions of αS with
Aβ40 and with Aβ42, both of which are largely extracellular, is
of interest in the light of the reported role extracellular αS may
play in neurodegeneration.50 The potential co-interaction of
αS WT with the tau construct k18 is of interest because both
Figure 2. Equilibrium populations of co-oligomers formed in 1:1 mixtures of the various protein combinations as indicated in the panels. A
total of two to five separate samples were studied at each concentration. Individual values are represented as purple crosses, and the fit to a
two-peptide model of oligomer formation is denoted by a solid line. The shaded bounds represent the fitting error, as in Figure 1. Note that
the apparent low oligomer concentrations in panels e and f are due to the lower monomer concentration ranges investigated (see the x axes).
In fact, these concentrations are predicted to be higher than for other co-oligomers over the same monomer concentration range.
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αS and tau proteins are predominantly intracellular and,
therefore, are likely to coexist under the same conditions.
To quantify the extent of co-oligomerization of the various
protein combinations, we combined and incubated 1:1
stoichiometric ratios of αS WT, singly labeled with AF488,
with each of these other proteins, singly labeled with AF594,
and selectively monitored the formation of co-oligomeric
species that contain both fluorophore labels by sm-TCCD
following the same protocols, as described above for the
detection of self-oligomers. The apparent oligomer concen-
trations measured in this way are shown in Figure 2, indicating
that co-oligomeric species are formed with all of the protein
combinations. The apparent equilibrium concentrations of co-
oligomers of αS WT and A30P (Figure 2a) can be seen to be
similar to the apparent concentrations of self-oligomers of αS
WT (Figure 1e). Interestingly, the apparent concentrations of
αS WT co-oligomers with A53T and E46K (Figure 2b,c) are
similar to the apparent concentrations of oligomers generated
by the mutational variants alone (Figure 1b,c), and are higher
than the apparent concentrations of the self-oligomers of αS
WT (Figure 1e). Our observation that αS WT can readily co-
oligomerize with all of the chosen mutational variants differs
from the conclusion of a relatively recent single-molecule study
that identified selectivity in the co-interactions with these
different mutants.23 The experimental conditions in the two
studies are, however, different and the incubations were carried
out over much longer time scales in the present experiments,
thus making the results not directly comparable. The observed
populations of co-oligomers between WT and k18 can be seen
to be below 20 nM over a similar monomer concentration
range (Figure 2d). Despite the low levels of such species, the
direct detection of co-oligomerization of αS with tau is
interesting, especially considering that there are at least six
major isoforms of tau in the human brain.51 The concen-
trations of co-oligomers between αS and Aβ detected appear
even lower but, in fact, can be predicted to be higher than for
all other co-oligomers when comparison is made over the same
initial monomer concentration range. This is also an
interesting result, especially given that multiple isoforms of
Aβ can be present in vivo.52 Indeed, it is likely that various
isoforms of tau or of Aβ may also co-assemble because the
extent of co-aggregation between different proteins is known to
be determined by the identity of their primary sequences.53
Theoretical Modeling of Self- and Co-Oligomer Data
Sets to Determine the Free Energies of Oligomer
formation. We then analyzed the data sets observed for self-
and co-oligomer formation by sm-TCCD (Figures 1 and 2)
using a statistical mechanical model similar to a previously
reported model.39 In this theoretical model, the key parameter
describing the oligomerization process is the Gibbs free energy
of monomer addition to an oligomer or another monomer,
ΔG°, independent of oligomer size, as illustrated schematically
in Figure 3a. This parameter characterizes the ease of oligomer
formation by monomeric species, and the more negative the
value, the more favorable the oligomerization.
In the present model, described in detail in the Methods
section, the oligomers were treated as simple non-interacting
one-dimensional chain structures with nearest-neighbor
interactions independent of chain length. The approximation
of non-interacting oligomers is reasonable given the very low
apparent concentrations of oligomers in the present experi-
ments. For self-oligomers, our model is identical to that
previously reported.39 Note that the modeling explicitly takes
into account the fact that only oligomers containing both
AF488 and AF594 dyes will be detected, whereas the singly
labeled oligomers are not detectable (see the Supporting
Information). The modeling of linear co-oligomers requires a
substantial new theory to be developed, detailed in the
Supporting Information “Co-Oligomer Modeling” section.
Under the present conditions, most oligomers are inferred to
be dimeric (see the Supporting Information “Oligomer Sizes”
section). Therefore, although we cannot rule out the existence
of larger nonlinear oligomeric species (e.g., tetrahedral clusters)
not explicitly included in our linear oligomer model, they
cannot in any case be present at sufficiently high concen-
trations under the present experimental conditions to
significantly affect our analysis. We test this by considering a
trimer-only model and a tetramer-only model, finding them to
give successively worse fits to the experimental data on self-
oligomers (see the Supporting Information “Justifying the
Choice of Model” section). Note that dimers are naturally
accounted for as the smallest aggregate species in our linear
model. We emphasize that oligomers have been shown to have
a different structure, stability, and toxicity compared to
fibrils;7,49 thus, our ΔG° is not the same as for fibril elongation.
Our model is not applicable to the analysis of the data
derived for the samples containing Aβ at the highest
concentrations investigated because we expect fibrillar
aggregates to exist at equilibrium above the critical aggregation
concentration for fibril formation, which is the lowest total
monomer concentration that is required for the formation of
fibrils.39 Using the same fitting procedure, we previously
Figure 3. Modeling of self- and co-oligomer formation. (a) Schematic representation of the two processes. The fitted values of free energies
of oligomerization, ΔG° values, derived from the analysis of sm-TCCD data for the formation (b) of self-oligomers and (c) of co-oligomers.
The standard errors in the ΔG° values were determined using a non-parametric bootstrap approach as defined in the Methods section. The
dotted line denotes the ΔG° for the formation of oligomers from WT.
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estimated these critical aggregation concentration values to be
222 ± 10 and 86 ± 10 nM for Aβ40 and Aβ42 isoforms,
respectively.39 Larger fibrillar aggregates were indeed observed
using TEM (Figure S1) in solutions containing either Aβ40 or
Aβ42 at a 3 μM concentration. Because Aβ comprises only half
of the protein molecules in the αS−Aβ solutions, we restricted
our analysis of these data sets to total protein concentrations
that were up to twice those previously derived critical
aggregation concentration values.
Following the fitting of self- and co-oligomer data sets, as
detailed in the Methods section, we derived the value of ΔG°
of oligomerization of all of the protein combinations
investigated in this study. The resulting values, summarized
in Figures 3b,c and listed in Table S1, are all large and negative,
similar in magnitude to the values previously reported for the
formation of Aβ40/42 oligomerizing systems.39 The least-
negative ΔG° value of −19.4 ± 0.5 kJ mol−1 was obtained for
k18, which is consistent with its lowest propensity to self-
assemble under our experimental conditions in the absence of
aggregation inducers. Interestingly, the resulting ΔG° value for
αS WT of −24.0 ± 0.3 kJmol−1 is less negative than the
resulting values for all mutational variants of αS except WT-
A30P. In addition, the ΔG° values for WT-Aβ co-oligomers
(−29.4 ± 0.6 kJmol−1 for WT-Aβ40 and −30.8 ± 1.0 kJmol−1
for WT-Aβ42) are more negative than the value for αS WT
and less negative than our previously obtained values for Aβ40
and Aβ42 self-oligomers (−36.3 kJmol−1 for both isoforms).39
Overall, the more-negative ΔG° values for the mixtures
containing the WT protein compared to αS WT alone suggest
that the co-oligomer formation by αS WT is more favorable
than the self-oligomer formation for most of the mixtures
under our experimental conditions.
Predicted Equilibrium Concentrations of Oligomer
Populations Based on the Derived Free Energies of
Oligomer Formation. The derivation of the free energies of
oligomer formation enables the prediction of the total rather
than apparent equilibrium concentrations of self- and co-
oligomers at any chosen protein concentration. Given that
oligomer concentrations depend exponentially on ΔG°s (as
detailed in Supporting Information), even slight differences in
the derived ΔG° values correspond to large differences in the
resulting equilibrium oligomer populations. Indeed, under the
present conditions, a stabilization of less than 2 kJ mol−1 is
sufficient to result in a doubling of the observed oligomer
concentration. To illustrate this statement, we set out to
explore the relative concentrations of different types of
oligomers formed by the mixtures of αS WT with its
mutational variants. To this end, we predicted the overall
oligomer concentrations and the concentrations of the separate
oligomer subpopulations for the 1:1 mixtures of WT with its
variant A30P, A53T, and E46K generated over the total range
of protein concentrations from 10 to 1000 nM and compared
them with the predicted oligomer populations for αS WT at
the same starting protein concentrations. These predictions
reveal that the co-oligomers of αS WT-A53T and WT-E46K
are the dominant sub-populations across the entire ranges of
the protein concentrations (Figure 4). In addition to the
concentrations of the self- and co-oligomer sub-populations in
the αS WT−mutational variant mixtures, we also predicted the
concentrations of oligomers for αS WT at a concentration of
αS of 1.5×, which is relevant to the scenario of αS
overproduction54,55 and corresponds to the conditions of its
gene duplication.56 According to these simulations, the total
oligomer concentration in the αS WT−mutational variant
mixtures can reach similar levels to the 1.5WT system, and
even-higher concentrations of oligomers are generated in the
case of WT-E46K combination.
Importantly, this analysis shows that the generation of high
concentrations of oligomers can be caused not only by the
increased concentration of soluble αS WT but also by the
presence of the protein variants that have a favorable
interaction with the αS WT owing to sequence similarity.53
The propensity identified in this study of the mutational
variants of αS to generate elevated equilibrium concentrations
of oligomers and co-oligomers may explain their pathogenicity,
along with other previously established disease-relevant
properties of these mutational variants such as perturbed
aggregation rates,17−19 altered binding to lipid membranes,21,57
and the altered structural organization of the oligomers.20
Subsequently, we used the derived ΔG°s to predict the
populations of the defined oligomeric species at the protein
concentrations that correspond to their physiological abun-
dance, focusing on the mixture of αS WT and Aβ isoforms.
Using the protein concentrations that might be present inside a
cell, 0.9 and 0.1 nM for Aβ40 and Aβ42, assuming their
intracellular concentrations are similar to their extracellular
Figure 4. Predicted equilibrium concentrations of protein oligomer populations over the concentration range of 10−1000 nM. In panels a−c,
the total concentrations of oligomers generated in 1:1 mixtures of αS WT-mutational variant are shown (“total”), and the separate oligomer
subpopulations that are present in these mixtures (co-oligomers are denoted as “mixed”, and the self-oligomers of either component as
“WT” and the corresponding mutational variant). In addition, αS WT self-oligomers generated at the same total protein concentrations are
shown (“1.0WT”), and the oligomers generated at 1.5 times higher total starting concentration of αS WT (“1.5WT”). Note that in panel b,
the curves “1.5WT” and “total” overlap.
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concentrations58 versus 300 nM for αS WT, based on the
measured Kd for membrane binding,
59 the major oligomeric
form is predicted to be self-oligomers of αS WT (0.96 nM),
followed by co-oligomers of αS WT and Aβ (0.05 nM and 0.01
nM for WT-Aβ40 and WT-Aβ42), with Aβ self-oligomers
being at concentrations that are orders of magnitude lower.
Thus, under these conditions, most of the Aβ peptides within
the oligomeric species are incorporated into the co-oligomers
with αS WT. At the protein concentrations that correspond to
their extracellular abundance in cerebrospinal fluid (CSF), (0.9
and 0.1 nM for Aβ40 and Aβ42 versus 1 nM for αS WT),41,58
the predicted dominant type of oligomer are self-oligomers of
Aβ40 (83%) at a concentration of 1.1 pM. Aβ42-containing
oligomers are present at 0.04 pM: 70% of these latter
oligomers are predicted to be co-oligomers of αS WT and
Aβ42, with 30% being self-oligomers of Aβ42. Remarkably,
most of Aβ42 is thus predicted to be a constituent of co-
oligomers under these conditions.
Co-Oligomer Formation Leading to Increased Cal-
cium Influx into Lipid Vesicles Due to Membrane
Disruption. Next, we set out to examine if the self- and co-
oligomers that αS forms with its mutational variants and with
the Aβ peptide are able to permeabilize lipid membranes, a
process that has been associated with neurotoxicity.60 We
addressed this question by measuring the oligomer-induced
permeabilization of lipid membranes using a recently
developed ultrasensitive single-vesicle assay that quantifies
Ca2+ influx into lipid vesicles upon membrane disruption based
on fluorescence-intensity changes of a calcium-sensitive dye.61
Using this assay and identical experimental conditions, we
previously reported that neither monomeric Aβ peptide nor
monomeric αS WT cause significant calcium influx;61 there-
fore, any influx observed can be attributed to the action of
peptide aggregates on the vesicle membranes. The detection of
a higher fluorescence intensity corresponds to a larger calcium
influx due to a higher level of membrane permeabilization
caused by the aggregates.61 First, we examined the action of αS
WT with and without its mutational variant E46K because this
combination of αS proteins generated the highest steady-state
concentrations of mixed oligomers and was expected to have
comparable lipid-binding properties and not to form lipid-
induced aggregates under our experimental conditions.
Separate solutions of 150 nM monomeric αS WT and of
150 nM monomeric αS E46K variant were prepared and
incubated under conditions for which we have characterized
the oligomer populations above (Figure 1e,c). We then
quantified the ability of these solutions to permeabilize
membranes using the single-vesicle assay,61 by measurement
of the total Ca2+ influx (Figure 5a). Significant Ca2+ influx was
observed in both cases, confirming that the self-oligomers
formed by these αS variants can disrupt membranes (see the
Methods section for further experimental details). We then
used our theoretical model to calculate the equilibrium
concentration of oligomers formed in each of these solutions
Figure 5. Quantification of the Ca2+ influx induced by oligomers using the single vesicle assay. (a) Experimentally measured average values of
Ca2+ influx, induced by the oligomers formed at equilibrium in solutions containing αS WT and E46K (concentrations in monomer
equivalents). Error bars correspond to the standard deviations from three separate experiments for each experimental condition (p =
0.0495). (b) Comparing self- and co-oligomer populations to their contributions to total Ca2+ influx, and their relative permeabilization
propensity, in the αS solution containing both 75 nM WT and 75 nM E46K. (c) Average values of Ca2+ influx induced by the oligomers
formed at equilibrium in solutions containing αS WT and Aβ42 (concentrations in monomer equivalents). Error bars correspond to the
standard deviations from four separate experiments for each experimental condition (p = 0.0209). (d) Comparing self- and co-oligomer
populations to their contributions to total Ca2+ influx, and their relative permeabilization propensity, in the solution containing both αS (40
nM WT) and Aβ42 (4 nM).
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(Table 1). Comparing these figures with the permeabilization
data allows us to quantitatively determine the ability of the
respective self-oligomers to induce Ca2+ influx [the permeabi-
lization propensity, measured in units of percentage point
(ppt) Ca2+ influx per picomole].
We next prepared solutions containing both monomeric αS
WT and the E46K variant at equimolar concentrations of 75
nM (total concentration of 150 nM) and incubated them
under the conditions described above to allow the formation of
oligomer populations. We then measured the ability of the
solutions containing these oligomer populations to cause Ca2+
influx in the vesicle assay (Figure 5a). We again used our
theoretical model to determine the concentrations of WT self-
oligomers (60 pM), E46K self-oligomers (370 pM), and WT-
E46K co-oligomers (740 pM) present in these solutions
(Figure 5b). Based on the concentrations of the self-oligomers
and their ability to induce Ca2+ influx that we have calculated
above, we can determine how much of the Ca2+ influx of the
mixture can be attributed to αS WT self-oligomers (3.7 ppt)
and αS E46K self-oligomers (5.6 ppt). The co-oligomers are
therefore responsible for 37.1 ppt of the Ca2+ influx. Dividing
this by the predicted co-oligomer concentration gives us the
permeabilization propensity of the WT-E46K co-oligomers.
These results show that although E46K-containing
oligomers are formed much more readily than WT oligomers
(Table 1), the ability of E46K self-oligomers to cause Ca2+
influx is lower compared with the αS WT-containing
oligomers, indicated by their lower permeabilization propensity
(Figure 5b). The co-oligomers both readily form and
significantly disrupt membranes and are thus responsible for
the great majority, namely 80%, of the observed Ca2+ influx
caused by the mixed αS WT-E46K solution (Figure 5b).
Because the toxicity of Aβ42 self-oligomers is also well-
established,61,62 it is of interest to test the potential toxicity of
αS WT-Aβ42 co-oligomers. Choosing monomeric concen-
trations at which co-oligomer formation was predicted to be
particularly high, we performed membrane permeabilization
experiments (Figure 5c) for solutions containing only self-
oligomers (generated from incubation of 4 nM Aβ42 or 40 nM
αS WT, respectively) and solutions containing self- and co-
oligomers (generated from incubation of 4 nM Aβ42 plus 40
nM αS WT). We employed our theoretical model to calculate
the concentrations of αS WT self-oligomers (17 pM), Aβ42
self-oligomers (20 pM), and WT-Aβ42 co-oligomers (49 pM)
formed in the mixed solution. Combined with theoretical
predictions of the oligomer concentrations formed in the
single-species solutions (Table 2), the data enabled us to
perform the same analysis as above to determine the relative
ability of these different oligomeric species to permeabilize
membranes. Our results show that although more than half of
the oligomers formed in the mixed solution are co-oligomers,
their contribution to the ability of the solution to permeabilize
membranes is small, and therefore, co-oligomers are
significantly less disruptive than the self-oligomers (Figure
5d). Interestingly, we also find that Aβ oligomers are over an
order of magnitude more disruptive to membranes than αS
oligomers and that they are present at similar concentrations
(Table 2). The greater number of co-oligomers in this case is
insufficient to outweigh the greater membrane permeabiliza-
tion propensity of Aβ42 self-oligomers, which remain
responsible for the majority (80%) of the Ca2+ influx caused
by the oligomers present in the WT-Aβ42 mixed solutions
(Figure 5d).
Because the αS WT protein coexists with its E46K variant in
the human brain of subjects displaying a single E46K mutation,
which means that the person carries one WT αS allele and one
allele with the E46K mutation, species formed during co-
aggregation may be involved in membrane permeabilization
and the loss of protein homeostasis. Our results show that the
presence of E46K mutation leads to the increased formation of
E46K self- and co-oligomers and not to these structures being
inherently more damaging to lipid membranes. Our results also
indicate substantial co-oligomerization between the PD-related
αS protein and the AD-associated Aβ42 peptide. However,
although this hints at a possible cross-seeding effect that may
have relevance for amyloid fibril formation, the co-oligomers
themselves appear to be relatively inert in the single-vesicle
assay compared with the self-oligomers of Aβ42 and, thus, may
have comparatively little direct effect on cell-membrane
disruption.
Taken together, our combined experimental and theoretical
methodology permits us not only to determine the
concentrations of different types of oligomers formed from
mixtures of amyloidogenic monomeric peptides and proteins at
biologically relevant concentrations but also to gain insight
into their likely relative toxicities due to lipid membrane
disruption. In addition, the close agreement between the
permeabilization propensity values calculated for αS self-
oligomers formed from 40 nM and 150 nM monomeric αS
solutions (Figure 5b,d) clearly demonstrates the self-
consistency of our modeling approach. The number of possible
cytotoxic αS-containing co-oligomer types can, in principle, be
very large in vivo, considering that new αS mutational variants
are still being discovered63,64 and numerous post-translation-
ally modified and truncated proteoforms of αS are physiolog-
ically abundant,65 as well as multiple isoforms of Aβ66 and
other amyloidogenic proteins and their complexes.67 More
generally, most proteins associated with neurodegenerative
diseases are found to be post-translationally modified in the
aggregated state so that the formation of co-oligomers, either
between different post-translationally modified forms of the
same protein or different proteins present in the same cellular
Table 1. Predicted Oligomer Concentrations for αS WT-
E46K Solutions
αS solution (initial
monomer
concentrations)
WT self-
oligomer
concentration
(pM)
E46K self-
oligomer
concentration
(pM)
WT-E46K co-
oligomer
concentration
(pM)
WT (150 nM) 240 − −
E46K (150 nM) − 1500 −
WT plus E46K (75
plus 75 nM)
60 370 740
Table 2. Predicted Oligomer Concentrations for αS WT-
Aβ42 Solutions
αS or Aβ solution
(initial monomer
concentrations)
WT self-
oligomer
concentration
(pM)
Aβ42 self-
oligomer
concentration
(pM)
WT-Aβ42 co-
oligomer
concentration
(pM)
αS WT (40 nM) 17 − −
Aβ42 (4 nM) − 21 −
WT plus Aβ42 (40
plus 4 nM)
17 20 49
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compartment, is likely to play a much more important role in
neurodegenerative diseases than previously thought.
CONCLUSIONS
In this study, we have performed a detailed quantitative
analysis of self- and co-oligomer formation by αS and its
mutational variants in vitro and investigated its co-oligomeriza-
tion with two major AD-related proteins, Aβ and tau k18
construct. We have compared the potential for lipid membrane
disruption by the different oligomer types using a single-vesicle
assay. Our results show that at low physiologically relevant
protein concentrations, co-oligomer formation in most cases is
more favorable than self-oligomer formation by αS, and thus,
αS-containing co-oligomers may be highly abundant under
conditions in which multiple proteins coexist. We also find that
although the co-oligomers examined are less potent membrane
disruptors in comparison to self-oligomers, their adverse effects
can become dominant when the co-oligomers are present at
high steady-state concentrations. The identified favorable
formation of co-oligomers between αS and other proteins
and the high potential of the resulting species to disrupt lipid
membranes are important in the context of synucleinopathies
and in the development of therapeutics against the onset and
progression of these diseases.
METHODS
Preparation of Self- and Co-Oligomer Samples. Monomeric
αS with an alanine to cysteine mutation, WT αS-A90C, A30P-A90C,
A53T-A90C, and E46K-A90C were expressed and purified based on
the protocol by Hoyer et al.68 and stored at −80 °C with the addition
of dithiothreitol. Fluorescent labeling at residue 90 was carried out
using Alexa Fluor (AF) 488 and 594 dyes (maleimide linkers,
Invitrogen Lifesciences) according to previously reported proto-
cols7,20,49 by incubating the protein with 1.5 molar excess of the AF
dyes overnight at 4 °C in degassed phosphate-buffered saline (PBS)
buffer (10 mM phosphate, 0.27 mM KCl and 137 mM NaCl at pH
7.4) and subsequent separation of the unreacted dyes on PD10
columns (GE Healthcare). The labeling efficiency was checked by
mass spectrometry and the samples with labeling efficiency above 95%
were selected (see the Supporting Information for representative
spectra). The expression and purification of k18 tau was performed as
previously reported,69 and labeling with the AF dyes was carried out
as for αS.7,20,49 Monomeric solutions of HiLyteFluor 488 (Anaspec,
Fremont) were prepared as described previously62,70 by dissolving the
lyophilized peptide in NaOH at pH 12, sonicating over ice for 15 min
(Bandelin Sonorex), and flash-freezing into aliquots and storing at
−80 °C. For the incubations, 1:1 molar ratios of 488- and 594-labeled
protein monomers were combined in PBS buffer (composition
defined above) up to the final volume of 900 μL, and the protein
combinations are shown in Figures 1 and 2. Note that in the co-
oligomerization experiments, a 1:1 molar ratio of AF488-labeled
protein variant is combined with a different protein variant that is
labeled with AF594, and thus, the species that contain both AF488
and AF594 correspond to the co-assemblies between the two protein
variants and the self-oligomers of either protein are not monitored. A
total of three separate samples for each concentration (in the range of
0−3 μM of total protein) and protein combination were prepared.
LoBind microcentrifuge test-tubes (Eppendorf, Hamburg, Germany)
were used for all incubations to prevent surface absorption, as had
been found to be effective in previous studies.20,48,49,71 Incubations
were performed for 3 days at 37 °C without agitation. Upon
withdrawal, the solutions were rapidly diluted to 100 pM
concentrations to enable single-molecule analysis and subsequently
analyzed using sm-TCCD.
TCCD Measurements and Data Analysis. TCCD measure-
ments were performed using a custom-built single-molecule
fluorescence microscope as previously described,49,69 utilizing fast-
flow microfluidics for sample detection48 and closely following
previously reported protocols.39 Dual-laser beam excitation was used
by exciting the solutions to be analyzed with collimated and
overlapped 488 nm (Spectra Physics NewPort Cyan) and 594 nm
(Cobolt Lasers) laser beams operating at 2 and 1.3 mW powers
(measured at the back port of the microscope), reflected by a dichroic
mirror (Semrock DiO1 R405/488/594), and sent through an oil
immersion objective (Plan Apo VC 60×, NA 1.40, Nikon) to be
focused 10 μm into the center of a microfluidic channel. The two laser
foci were visualized using a CCD camera and overlapped by manually
adjusting their shapes and positions in the xy plane. The laser beam
overlap was routinely checked by a stationary measurement using a
dual-labeled (with 1:1 AF488 and AF594) 40-bp TCCD DNA duplex
at 25 pM concentration following previously published procedures,48
and the alignment was regularly carried out prior to protein
measurements to ensure maximum beam overlap. Fluorescence signal
was collected by the same objective, imaged onto a 100 μm pinhole
(Thorlabs), and separated into two channels by a dichroic mirror
(Horiba 585DRLP). The pinhole was conjugate with the plane of
focus of the microscope objective and the point of the laser excitation
and, thus, eliminated out-of-focus fluorescence and scattered light and
reduced the background noise. Donor fluorescence was filtered by a
long-pass (Edge Basic 514) and a band-pass filter (535AF45 Omega
Filters) before being focused onto an avalanche photodiode, APD
(PerkinElmer). Acceptor fluorescence was directed through a long-
pass filter (610ALP Horiba) and a band-pass filter (BrightLine 629/
53) before being focused onto a second APD. Synchronous output
from the APDs was collected by custom-implemented field-program-
mable gate array, FPGA (Celoxica RC10). Data were acquired for 600
s (60 frames, 100 000 bins per frame, 100 μs bin-width) per aliquot
and consisted of time-binned photon bursts in the donor and the
acceptor channel. All measurements were made at ambient temper-
ature around 20 °C.
The collected photon traces were analyzed using custom-written
Igor Pro 6.22 (Wavemetrics) software analogous to that previously
described.48 The data were corrected for autofluorescence and for
cross-talk. Photon bursts with intensities greater than the threshold of
15 photons per bin in the blue and, in the red channels, were selected
according to previously established threshold selection approaches
that allowed maximization of the detection of coincident events.
Simultaneous events in both channels above the threshold (the AND
criterion)72 were selected. To account for any possible coincident
events due to chance, the desynchronization approach was used.73
Time-bins in the blue channel were randomly renumbered before the
selection of simultaneous events in the two channels above the
threshold. Using these outputs, the association quotient Q was
estimated according to eq 1:
= −
+ − −
Q
C E
A B C E( ) (1)
where A is the number of fluorescent bursts in the blue channel, B is
the number of fluorescent bursts in the red channel, C is the number
of coincident events, and E is the number of chance-coincident events
(all above the 15 photons per bin threshold). The apparent oligomer
concentrations, presented in Figures 1 and 2, were defined as the
fraction of coincident events (oligomers) multiplied by the starting
total protein concentration.
Modeling of Self- and Co-Oligomer Data Sets. Having
ascertained that the experiments detailed here have reached
equilibrium with respect to oligomer formation (Figure S2), we
analyzed our results using two equilibrium statistical mechanical
models: a previously described single-peptide oligomerization
model39 and a new two-peptide model of co-oligomer formation.
The first model considers a solution of a single species of monomeric
peptide that can reversibly self-associate to form linear chains of any
length. The second model consists of a solution containing two
species of monomeric peptide that can reversibly associate to form
both mixed- and single-species chains. The equilibrium constants of
these reactions can be related to the free energies of monomer
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addition to like and unlike peptides or to self- and co-oligomerization.
We work in the grand canonical ensemble, and we set the chemical
potentials by insisting on conservation of peptide. Furthermore, we
consider concentrations not numbers; thus, the only free thermody-
namic parameter is the temperature. Thus, the systems described by
both models are completely specified by the standard free energies,
the peptide concentrations, and the temperature. We can therefore
determine the standard free energies by least-squares fitting the
apparent oligomer concentrations as a function of initial monomer
concentrations.
We first fit the self-oligomer data to the single-species model to
obtain the self-oligomerization standard free energies. Note that the
model contains a correction factor (calculated exactly analytically) to
account for the fact that only the oligomers containing both AF488
and AF594 dye are detected by the experimental measurements, with
AF488-only and AF594r-only oligomers being invisible. We then
enter these free energies into the two-species model, which we fit to
the two-species oligomerization data to determine the co-oligomeriza-
tion standard free energy. These data only measure the co-oligomer
concentration, so we fit only to the mixed oligomer component of the
model.
Due to the complicated analytical fitting procedure, a formal
parametric approach to error estimation is not suitable. Therefore, we
prefer to use a nonparametric bootstrap approach.74 Our data are
effectively stratified by initial monomer concentration; therefore, we
also stratify our sampling to better reproduce the structure of the data
in our resamples.75 Furthermore, we prefer a subsampling technique
rather than full bootstrap because subsampling is valid under much-
weaker conditions than full resampling.76 Our full method is then to
randomly sample one data point at each monomer concentration and
fit the resulting subdata set to our model, recording the resultant ΔG°.
This process is then repeated many times (we chose to do 500
repeats), generating a distribution of ΔG°. An estimate of the
standard error for ΔG° is then given by the standard deviation of this
distribution.
Quantification of Ca2+ Influx into Lipid Vesicles. Protein
samples were prepared and incubated under the same incubation
conditions as for the sm-TCCD assays using unlabeled αS WT,
unlabeled E46K, and unlabeled Aβ42 at the total starting protein
concentrations as specified in Figure 5. For the detailed description of
the preparation of Aβ42 peptide stock and for details on the single-
vesicle method, see Flagmeier et al.61 Briefly, lipid vesicles were
composed of 16:0−18:1 PC and 18:1−12:0 biotin PC at a 100:1 ratio
and filled with 100 μM Cal-520 in HEPES buffer of pH 6.5. This type
of lipids was chosen after testing several different lipid compositions,
as detailed before,61 because it enabled the preparation of a fluid
bilayer at room temperature. Even though other lipid compositions
can have this property, we avoided using negatively charged lipids due
to reported increased binding of E46K mutational variant in
comparison to WT αS in their presence.77,78 Multiple freeze-and-
thaw cycles and extrusion using a membrane of 200 nm cutoff were
performed. Then, size-exclusion chromatography was carried out to
separate non-incorporated dye molecules from the vesicles.
Subsequently, the purified vesicles were immobilized onto PLL−
PEG coated glass coverslips using a biotin−neutravidin−biotin
linkage and incubated in 50 μL Ca2+ containing Leibovitz’s L-15
solution and were imaged using total internal reflection fluorescence
microscopy. Thereafter, 50 μL of protein solution was added, and the
same area of the coverslips was imaged to check if the solution
induced any influx of Ca2+ into the vesicles. Next, ionomycin, an
ionophore for cations, was added and incubated for 5 min. Ionomycin
allows Ca2+ to enter the vesicles and saturates them with Ca2+.
Subsequently, images of Ca2+ saturated single vesicles of the same area
were acquired. For each field of view, 50 images were taken with an
exposure time of 50 ms. The recorded images were used to determine
the fluorescence intensity of each spot under the three different
conditions: in the presence of only buffer namely blank (Fblank), in the
presence of an aggregation mixture (Fsample), and after the addition of
ionomycin (FIonomycin). The detection of individual spots was
implemented using “find maxima”, and the intensity of the spots
was calculated by considering a 5 pixel diameter. Finally, the sample-
induced relative Ca2+ influx into a vesicle was quantified using the
following equation:
=
−
−
+ F F
F F
Ca influx2 sample blank
ionomycin blank (2)
The average degree and standard deviation of Ca2+ influx was
calculated by averaging the Ca2+ influx into individual vesicle from
nine fields of view. P values reported in Figure 5 are obtained using a
Kruskal−Wallis test with α = 0.05. Data from just premixed versus
incubated protein samples are compared.
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Trois? ChemBioChem 2015, 16, 2319−2328.
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